Myeloma Drug's Comeback Nixed by FDA Panel

(MedPage Today) — The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the drug does not have a favorable benefit-risk profile in combination with either…